Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 15/20 | 0.39 |
| ▸ | JAK1 | P23458 | 15/20 | 0.39 |
| ▸ | TYK2 | P29597 | 15/20 | 0.39 |
| ▸ | JAK3 | P52333 | 15/20 | 0.39 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.38 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.33 |
| ▸ | ITK | Q08881 | 2/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31489249 | 1.00 | JAK2 (0.39) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489438 | 0.86 | CYP17A1 (0.40) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489819 | 0.86 | CYP17A1 (0.40) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489347 | 0.84 | CREBBP (0.42) | CYP17A1 | |
| SCHEMBL31489258 | 0.84 | CREBBP (0.42) | CYP17A1 | |
| SCHEMBL31489575 | 0.81 | GABRA1 (0.32) | JAK2JAK1TYK2JAK3MKNK1 | |
| SCHEMBL31489349 | 0.81 | GABRA1 (0.32) | JAK2JAK1TYK2JAK3MKNK1 | |
| SCHEMBL31489590 | 0.79 | CYP17A1 (0.38) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489746 | 0.79 | CYP17A1 (0.38) | JAK2JAK1TYK2JAK3CYP17A1 | |
| SCHEMBL31489266 | 0.77 | CYP17A1 (0.40) | JAK2JAK1TYK2JAK3CYP17A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025072395-A1 | TRIAZOLOPYRIDINYL COMPOUNDS AS KINASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2025-04-03 | — | — | WO | disclosed |